Clotilde Mircher
Research Subjects
Clotilde Mircher has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Isabelle Marey
Institut Jérôme Lejeune, Paris, France
5 shared publicationsAimé Ravel
Institut Jérôme Lejeune, Paris, France
4 shared publications- Franck Sturtz
Universite de Limoges Faculte de Pharmacie
4 shared publications Jeanne Toulas
Institut Jérôme Lejeune, Paris, France
4 shared publications- Cecile Cieuta-Walti
Institut Jérôme Lejeune, Paris, France
3 shared publications Martine Conte
Jerome Lejeune Institute, Paris, France
3 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 216
Long-term benefits of early obstructive sleep apnea treatment in infants with Down syndrome
- 5 November 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 216
Open AccessLong-term benefits of early obstructive sleep apnea treatment in infants with Down syndrome
- Open Access
- 3 July 2025
- Published by LIDSEN Publishing Inc in OBM Genetics
- Vol. 09 (03) , 1-22
Gut Microbial Similarity Analysis in Mono and Dizygotic Twins Discordant for Down Syndrome
To investigate the potential impact of the additional chromosome 21 on the gut microbiome in patients with Down syndrome (DS), two monozygotic (MZ) and two dizygotic (DZ) twin pairs discordant for DS were studied. Whole-genome shotgun sequencing was conducted to analyze the taxonomic and functional profiles of the gut microbial community in the twins and assess whether the gut microbiome composition influences the development of psychological pathologies. Sequencing generated a total of 2,338,132 reads, combined across the four samples. The number of contigs ranged from 98,521 to 122,000, and the GC content was 46.34-47.15%. The Simpson index at the species level in the DS of our study was distinctly higher in the DZ-DS but not in the MZ-DS. Taxonomic classification revealed a Western diversity profile in the twins, where the dominant bacterial phyla were Firmicutes, Bacteroidetes, and Actinomycetota. Each sample had a diversity of ten families at abundance >0.5%, of which Prevotellaceae, Lachnospiraceae, and Bacteroidaceae were the most prevalent. The Prevotellaceae family was detected at a high level in all samples, except in the DZ-DS, where Lachnospiraceae was the most abundant family. At the genus level, marked differences were observed between the DZ-DS twins compared to the others. Prevotella was not detected in the DZ-DS twin whereas it was the dominant genus in the MZ-DS and both healthy twins. The variation in predicted metagenomes between DS and non-DS showed that the average relative abundances for DS were comparable to those for non-DS. The two MZ twins discordant for DS appear to have relatively similar microbiomes, suggesting that the added chromosome 21 did not have a significant impact on gut microbiome composition. Identifying biomarkers of DS that modulate the gut composition and affect the overall health needs to be further studied, along with the potential role of Prevotella.
- 3 July 2025
- Published by LIDSEN Publishing Inc in OBM Genetics
- Vol. 09 (03) , 1-22
Open AccessGut Microbial Similarity Analysis in Mono and Dizygotic Twins Discordant for Down Syndrome
To investigate the potential impact of the additional chromosome 21 on the gut microbiome in patients with Down syndrome (DS), two monozygotic (MZ) and two dizygotic (DZ) twin pairs discordant for DS were studied. Whole-genome shotgun sequencing was conducted to analyze the taxonomic and functional profiles of the gut microbial community in the twins and assess whether the gut microbiome composition influences the development of psychological pathologies. Sequencing generated a total of 2,338,132 reads, combined across the four samples. The number of contigs ranged from 98,521 to 122,000, and the GC content was 46.34-47.15%. The Simpson index at the species level in the DS of our study was distinctly higher in the DZ-DS but not in the MZ-DS. Taxonomic classification revealed a Western diversity profile in the twins, where the dominant bacterial phyla were Firmicutes, Bacteroidetes, and Actinomycetota. Each sample had a diversity of ten families at abundance >0.5%, of which Prevotellaceae, Lachnospiraceae, and Bacteroidaceae were the most prevalent. The Prevotellaceae family was detected at a high level in all samples, except in the DZ-DS, where Lachnospiraceae was the most abundant family. At the genus level, marked differences were observed between the DZ-DS twins compared to the others. Prevotella was not detected in the DZ-DS twin whereas it was the dominant genus in the MZ-DS and both healthy twins. The variation in predicted metagenomes between DS and non-DS showed that the average relative abundances for DS were comparable to those for non-DS. The two MZ twins discordant for DS appear to have relatively similar microbiomes, suggesting that the added chromosome 21 did not have a significant impact on gut microbiome composition. Identifying biomarkers of DS that modulate the gut composition and affect the overall health needs to be further studied, along with the potential role of Prevotella.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S22)
TRIAL21: A COHORT OF ADULTS WITH DOWN SYNDROME AT RISK OF DEVELOPING ALZHEIMER'S DISEASE
Background: Trisomy 21, in addition to being the first cause of intellectual disability, confers a high risk of developing Alzheimer’s disease (AD). The APP (Amyloid Precursor Protein) gene is located on chromosome 21, leading to high levels of ß‐amyloid peptide. However, there is great variability in the age of onset of symptoms.The objective of this study is to identify factors influencing the age of onset of the disease by following a cohort of adults with trisomy 21Method: This is a prospective, single‐center, open‐label study. A total of 200 patients aged at least 35 years without a diagnosis of AD at baseline will be included.Baseline visit includes a medical examination, a neuropsychological evaluation, a blood sample and a lumbar puncture (if possible). A brain MRI is performed within 3 months. A medical visit takes place at 12 months. The end‐of‐study visit at 24 months includes a medical examination, a neuropsychological evaluation and a blood sample. An annual follow‐up for 10 years in the care setting is provided.Result: Between April 2019 and January 2023, 119 patients were included, including 55 women and 64 men. The average age was 48 years.25 lumbar punctures and 90 brain MRI could be performed, as 86 visits at 12 months and 44 visits at 24 months.Conclusion: Early changes related to AD are particularly difficult to detect in adults with Trisomy 21 because of their intellectual disability. The identification of progression factors of the disease is essential to allow an early diagnosis for an appropriate management
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S22)
Open AccessTRIAL21: A COHORT OF ADULTS WITH DOWN SYNDROME AT RISK OF DEVELOPING ALZHEIMER'S DISEASE
Background: Trisomy 21, in addition to being the first cause of intellectual disability, confers a high risk of developing Alzheimer’s disease (AD). The APP (Amyloid Precursor Protein) gene is located on chromosome 21, leading to high levels of ß‐amyloid peptide. However, there is great variability in the age of onset of symptoms.The objective of this study is to identify factors influencing the age of onset of the disease by following a cohort of adults with trisomy 21Method: This is a prospective, single‐center, open‐label study. A total of 200 patients aged at least 35 years without a diagnosis of AD at baseline will be included.Baseline visit includes a medical examination, a neuropsychological evaluation, a blood sample and a lumbar puncture (if possible). A brain MRI is performed within 3 months. A medical visit takes place at 12 months. The end‐of‐study visit at 24 months includes a medical examination, a neuropsychological evaluation and a blood sample. An annual follow‐up for 10 years in the care setting is provided.Result: Between April 2019 and January 2023, 119 patients were included, including 55 women and 64 men. The average age was 48 years.25 lumbar punctures and 90 brain MRI could be performed, as 86 visits at 12 months and 44 visits at 24 months.Conclusion: Early changes related to AD are particularly difficult to detect in adults with Trisomy 21 because of their intellectual disability. The identification of progression factors of the disease is essential to allow an early diagnosis for an appropriate management
- Open Access
- 1 August 2022
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 5 (12) , e202101205
Chr21 protein–protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer’s disease
Down syndrome (DS) is caused by human chromosome 21 (HSA21) trisomy. It is characterized by a poorly understood intellectual disability (ID). We studied two mouse models of DS, one with an extra copy of theDyrk1Agene (189N3) and the other with an extra copy of the mouse Chr16 syntenic region (Dp(16)1Yey). RNA-seq analysis of the transcripts deregulated in the embryonic hippocampus revealed an enrichment in genes associated with chromatin for the 189N3 model, and synapses for the Dp(16)1Yey model. A large-scale yeast two-hybrid screen (82 different screens, including 72 HSA21 baits and 10 rebounds) of a human brain library containing at least 107independent fragments identified 1,949 novel protein–protein interactions. The direct interactors of HSA21 baits and rebounds were significantly enriched in ID-related genes (P-value < 2.29 × 10−8). Proximity ligation assays showed that some of the proteins encoded by HSA21 were located at the dendritic spine postsynaptic density, in a protein network at the dendritic spine postsynapse. We located HSA21 DYRK1A and DSCAM, mutations of which increase the risk of autism spectrum disorder (ASD) 20-fold, in this postsynaptic network. We found that an intracellular domain of DSCAM bound either DLGs, which are multimeric scaffolds comprising receptors, ion channels and associated signaling proteins, or DYRK1A. The DYRK1A-DSCAM interaction domain is conserved inDrosophilaand humans. The postsynaptic network was found to be enriched in proteins associated with ARC-related synaptic plasticity, ASD, and late-onset Alzheimer’s disease. These results highlight links between DS and brain diseases with a complex genetic basis.
- 1 August 2022
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 5 (12) , e202101205
Open AccessChr21 protein–protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer’s disease
Down syndrome (DS) is caused by human chromosome 21 (HSA21) trisomy. It is characterized by a poorly understood intellectual disability (ID). We studied two mouse models of DS, one with an extra copy of theDyrk1Agene (189N3) and the other with an extra copy of the mouse Chr16 syntenic region (Dp(16)1Yey). RNA-seq analysis of the transcripts deregulated in the embryonic hippocampus revealed an enrichment in genes associated with chromatin for the 189N3 model, and synapses for the Dp(16)1Yey model. A large-scale yeast two-hybrid screen (82 different screens, including 72 HSA21 baits and 10 rebounds) of a human brain library containing at least 107independent fragments identified 1,949 novel protein–protein interactions. The direct interactors of HSA21 baits and rebounds were significantly enriched in ID-related genes (P-value < 2.29 × 10−8). Proximity ligation assays showed that some of the proteins encoded by HSA21 were located at the dendritic spine postsynaptic density, in a protein network at the dendritic spine postsynapse. We located HSA21 DYRK1A and DSCAM, mutations of which increase the risk of autism spectrum disorder (ASD) 20-fold, in this postsynaptic network. We found that an intracellular domain of DSCAM bound either DLGs, which are multimeric scaffolds comprising receptors, ion channels and associated signaling proteins, or DYRK1A. The DYRK1A-DSCAM interaction domain is conserved inDrosophilaand humans. The postsynaptic network was found to be enriched in proteins associated with ARC-related synaptic plasticity, ASD, and late-onset Alzheimer’s disease. These results highlight links between DS and brain diseases with a complex genetic basis.
- 4 December 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (3) , 818-827
Psychomotor development in infants and young children with Down syndrome—A prospective, repeated measure, post‐hoc analysis
Children with Down syndrome (DS) show delayed acquisition of cognitive and functional skills compared to typically developing children. The objective of this study was to accurately describe early development of infants and young children (children hereafter) with DS based on a large recent sample. We carried out repeated measure analysis of the global development quotient (GDQ) and developmental age using data from the Assessment of Systematic Treatment with Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children (ACTHYF) study (NCT01576705). Because there was no statistically significant difference in the primary endpoint between active treatment and placebo, data from all treatment groups were pooled for post‐hoc analysis. Data of 141 children with DS aged 6–18 months at inclusion were analyzed. Mean GDQ decreased over the study period, especially in the youngest age classes ([6–9] and [9–12] months), indicating that acquisition of skills occurred at a slower pace compared to typically developing children. Strongest deficits were observed for motor and hearing and language skills. Only GDQ at baseline correlated significantly with evolution of GDQ. Future studies should aim at elucidating the mechanisms underlying motor and language development. Early pharmacological interventions together with early childhood therapies might be necessary to improve the developmental trajectory of children with DS.
- 4 December 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (3) , 818-827
Psychomotor development in infants and young children with Down syndrome—A prospective, repeated measure, post‐hoc analysis
Children with Down syndrome (DS) show delayed acquisition of cognitive and functional skills compared to typically developing children. The objective of this study was to accurately describe early development of infants and young children (children hereafter) with DS based on a large recent sample. We carried out repeated measure analysis of the global development quotient (GDQ) and developmental age using data from the Assessment of Systematic Treatment with Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children (ACTHYF) study (NCT01576705). Because there was no statistically significant difference in the primary endpoint between active treatment and placebo, data from all treatment groups were pooled for post‐hoc analysis. Data of 141 children with DS aged 6–18 months at inclusion were analyzed. Mean GDQ decreased over the study period, especially in the youngest age classes ([6–9] and [9–12] months), indicating that acquisition of skills occurred at a slower pace compared to typically developing children. Strongest deficits were observed for motor and hearing and language skills. Only GDQ at baseline correlated significantly with evolution of GDQ. Future studies should aim at elucidating the mechanisms underlying motor and language development. Early pharmacological interventions together with early childhood therapies might be necessary to improve the developmental trajectory of children with DS.
- Open Access
- 1 May 2021
- Published by Elsevier in Neurobiology of Stress
- Vol. 14, 100305
Deciphering the links between psychological stress, depression, and neurocognitive decline in patients with Down syndrome
- 1 May 2021
- Published by Elsevier in Neurobiology of Stress
- Vol. 14, 100305
Open AccessDeciphering the links between psychological stress, depression, and neurocognitive decline in patients with Down syndrome
- 1 January 2020
- Published by Elsevier in Genetics in Medicine
- Vol. 22 (1) , 44-52
Thyroid hormone and folinic acid in young children with Down syndrome: the phase 3 ACTHYF trial
- 1 January 2020
- Published by Elsevier in Genetics in Medicine
- Vol. 22 (1) , 44-52
Thyroid hormone and folinic acid in young children with Down syndrome: the phase 3 ACTHYF trial
- Open Access
- 16 December 2019
- Published by Springer Nature in Clinical Epigenetics
- Vol. 11 (1) , 1-11
Methylomic profiling in trisomy 21 identifies cognition- and Alzheimer’s disease-related dysregulation
Background: Trisomy 21 (T21) is associated with intellectual disability that ranges from mild to profound with an average intellectual quotient of around 50. Furthermore, T21 patients have a high risk of developing Alzheimer’s disease (AD) early in life, characterized by the presence of senile plaques of amyloid protein and neurofibrillary tangles, leading to neuronal loss and cognitive decline. We postulate that epigenetic factors contribute to the observed variability in intellectual disability, as well as at the level of neurodegeneration seen in T21 individuals. Materials and Methods: A genome-wide DNA methylation study was performed using Illumina Infinium® MethylationEPIC BeadChips on whole blood DNA of 3 male T21 patients with low IQ, 8 T21 patients with high IQ (4 males and 4 females), and 21 age- and sex-matched control samples (12 males and 9 females) in order to determine whether DNA methylation alterations could help explain variation in cognitive impairment between individuals with T21. In view of the increased risk of developing AD in T21 individuals, we additionally investigated the T21-associated sites in published blood DNA methylation data from the AgeCoDe cohort (German study on Ageing, Cognition, and Dementia). AgeCoDe represents a prospective longitudinal study including non-demented individuals at baseline of which a part develops AD dementia at follow-up. Results: Two thousand seven hundred sixteen differentially methylated sites and regions discriminating T21 and healthy individuals were identified. In the T21 high and low IQ comparison, a single CpG located in the promoter of PELI1 was differentially methylated after multiple testing adjustment. For the same contrast, 69 differentially methylated regions were identified. Performing a targeted association analysis for the significant T21-associated CpG sites in the AgeCoDe cohort, we found that 9 showed significant methylation differences related to AD dementia, including one in the ADAM10 gene. This gene has previously been shown to play a role in the prevention of amyloid plaque formation in the brain. Conclusion: The differentially methylated regions may help understand the interaction between methylation alterations and cognitive function. In addition, ADAM10 might be a valuable blood-based biomarker for at least the early detection of AD.
- 16 December 2019
- Published by Springer Nature in Clinical Epigenetics
- Vol. 11 (1) , 1-11
Open AccessMethylomic profiling in trisomy 21 identifies cognition- and Alzheimer’s disease-related dysregulation
Background: Trisomy 21 (T21) is associated with intellectual disability that ranges from mild to profound with an average intellectual quotient of around 50. Furthermore, T21 patients have a high risk of developing Alzheimer’s disease (AD) early in life, characterized by the presence of senile plaques of amyloid protein and neurofibrillary tangles, leading to neuronal loss and cognitive decline. We postulate that epigenetic factors contribute to the observed variability in intellectual disability, as well as at the level of neurodegeneration seen in T21 individuals. Materials and Methods: A genome-wide DNA methylation study was performed using Illumina Infinium® MethylationEPIC BeadChips on whole blood DNA of 3 male T21 patients with low IQ, 8 T21 patients with high IQ (4 males and 4 females), and 21 age- and sex-matched control samples (12 males and 9 females) in order to determine whether DNA methylation alterations could help explain variation in cognitive impairment between individuals with T21. In view of the increased risk of developing AD in T21 individuals, we additionally investigated the T21-associated sites in published blood DNA methylation data from the AgeCoDe cohort (German study on Ageing, Cognition, and Dementia). AgeCoDe represents a prospective longitudinal study including non-demented individuals at baseline of which a part develops AD dementia at follow-up. Results: Two thousand seven hundred sixteen differentially methylated sites and regions discriminating T21 and healthy individuals were identified. In the T21 high and low IQ comparison, a single CpG located in the promoter of PELI1 was differentially methylated after multiple testing adjustment. For the same contrast, 69 differentially methylated regions were identified. Performing a targeted association analysis for the significant T21-associated CpG sites in the AgeCoDe cohort, we found that 9 showed significant methylation differences related to AD dementia, including one in the ADAM10 gene. This gene has previously been shown to play a role in the prevention of amyloid plaque formation in the brain. Conclusion: The differentially methylated regions may help understand the interaction between methylation alterations and cognitive function. In addition, ADAM10 might be a valuable blood-based biomarker for at least the early detection of AD.
- 20 December 2018
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 176 (12) , 2685-2694
Growth curves for French people with Down syndrome from birth to 20 years of age
We present new and complete growth charts for 2,598 healthy French children and adolescents with Down syndrome (DS) from 0 to 20 years old, obtained with highly reliable statistical methods. This study is retrospective and addresses data collected over a period of 12 years, monocentric and with a satisfactory representation of the population nationwide. Final occipito‐frontal circumference (OFC) is at the fifth percentile compared to WHO charts, with a drop between 12 and 18 months. Final height is at the first percentile compared to WHO charts for girls and boys with two periods of reduced growth velocity: before 36 months and around puberty. We observed no pubertal growth peak for girls. For boys, pubertal growth peak showed to happen earlier and to be less significant than in the general population. When compared to a previous French study with people affected with DS, pubertal growth acceleration begins at a later age for girls and boys; girls in our study are taller at age 15 (+5 cm), but there is no difference for boys at this age. Overweight is more frequent compared to the typical French population. Mean body mass index (BMI) rises rapidly above the 75th percentile of typical French children as early as age 4, with an earlier age for precocious adiposity rebound. The second period for rapid increase of BMI is around 14 years old. When compared to a previous French study with DS, we did not observe any BMI increase, at least up to the age of 14.
- 20 December 2018
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 176 (12) , 2685-2694
Growth curves for French people with Down syndrome from birth to 20 years of age
We present new and complete growth charts for 2,598 healthy French children and adolescents with Down syndrome (DS) from 0 to 20 years old, obtained with highly reliable statistical methods. This study is retrospective and addresses data collected over a period of 12 years, monocentric and with a satisfactory representation of the population nationwide. Final occipito‐frontal circumference (OFC) is at the fifth percentile compared to WHO charts, with a drop between 12 and 18 months. Final height is at the first percentile compared to WHO charts for girls and boys with two periods of reduced growth velocity: before 36 months and around puberty. We observed no pubertal growth peak for girls. For boys, pubertal growth peak showed to happen earlier and to be less significant than in the general population. When compared to a previous French study with people affected with DS, pubertal growth acceleration begins at a later age for girls and boys; girls in our study are taller at age 15 (+5 cm), but there is no difference for boys at this age. Overweight is more frequent compared to the typical French population. Mean body mass index (BMI) rises rapidly above the 75th percentile of typical French children as early as age 4, with an earlier age for precocious adiposity rebound. The second period for rapid increase of BMI is around 14 years old. When compared to a previous French study with DS, we did not observe any BMI increase, at least up to the age of 14.
- 2 June 2017
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 173 (8) , 2166-2175
Anthropometric charts and congenital anomalies in newborns with Down syndrome
The objectives of this study were to obtain updated neonatal measurements in French newborns with Down Syndrome (DS) according to their gestational age, and to assess the frequency and distribution of congenital anomalies. Data on congenital malformations, birth weight, birth length and birth occipito‐frontal circumference (OFC) according to the gestational age was gathered from 1,030 babies, born between 1980 and 2010. The mean gestational age was 38 weeks from the date of the last menstrual period (LMP) (range: 29–42 weeks). Repartition of complications was found to be similar to previous studies, with no difference according to the date of birth. For girls born after 37 weeks, the mean birth weight was 3,012 ± 430 g, the mean birth length was 47.7 ± 2 cm, and the mean birth OFC was 33 ± 1.4 cm. For boys born after 37 weeks, the mean birth weight was 3,103 ± 459, the mean birth length was 48.4 ± 2.2 cm, and the mean birth OFC was 33.2 ± 1.4 cm. We did not find any difference in these measurements when we compared children born before 1997 and after 2007. When compared to the general population (French data and WHO charts), newborns with DS have a more pronounced difference in their birth length and their birth OFC (15–25th) than in their birth weight (25–50th). The shape of the growth curves shows that growth velocity decreases during the last weeks of gestation in all measurements, which suggests that the modal age for delivery could be earlier in DS newborns than in the general population.
- 2 June 2017
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 173 (8) , 2166-2175
Anthropometric charts and congenital anomalies in newborns with Down syndrome
The objectives of this study were to obtain updated neonatal measurements in French newborns with Down Syndrome (DS) according to their gestational age, and to assess the frequency and distribution of congenital anomalies. Data on congenital malformations, birth weight, birth length and birth occipito‐frontal circumference (OFC) according to the gestational age was gathered from 1,030 babies, born between 1980 and 2010. The mean gestational age was 38 weeks from the date of the last menstrual period (LMP) (range: 29–42 weeks). Repartition of complications was found to be similar to previous studies, with no difference according to the date of birth. For girls born after 37 weeks, the mean birth weight was 3,012 ± 430 g, the mean birth length was 47.7 ± 2 cm, and the mean birth OFC was 33 ± 1.4 cm. For boys born after 37 weeks, the mean birth weight was 3,103 ± 459, the mean birth length was 48.4 ± 2.2 cm, and the mean birth OFC was 33.2 ± 1.4 cm. We did not find any difference in these measurements when we compared children born before 1997 and after 2007. When compared to the general population (French data and WHO charts), newborns with DS have a more pronounced difference in their birth length and their birth OFC (15–25th) than in their birth weight (25–50th). The shape of the growth curves shows that growth velocity decreases during the last weeks of gestation in all measurements, which suggests that the modal age for delivery could be earlier in DS newborns than in the general population.